RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients

2024-01-12

临床2期快速通道抗体药物偶联物临床申请临床1期

YANTAI, China, Jan. 12, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced recently that its independently developed mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), RC88, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers. This marks another significant development following the FDA's approval to RC88's international multicenter Phase II clinical trials last month.

RC88 consists of a recombinant humanized anti-MSLN monoclonal antibody linked to the microtubule inhibitor monomethyl auristatin E (MMAE), which acts as a microtubule inhibitor. It has a high affinity for MSLN, which can specifically bind to overexpressing MSLN tissues, and has clearly displayed a terminating effect on tumor cells with various expression levels of MSLN.

Epithelial ovarian cancer (EOC) is the leading cause of cancer-related deaths in women, often diagnosed late and prone to relapse within two years, with their disease evolving from platinum-sensitive to resistant. The later the stage and the more aggressive the ovarian cancer, the higher the expression rate of MSLN, and current treatment options are limited. RC88 uniquely targets MSLN, offering a novel approach to this challenging medical condition.

FTD is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill unmet medical needs. The purpose behind this is to get important new drugs to the patient earlier.

Reflecting on this process, Dr. Jianmin Fang, CEO of RemeGen, said, "The FDA's FTD accelerates the development and review process of RC88, which affirms our commitment to pioneering treatments that address the urgent needs of those facing challenging disease. Moving forward, RemeGen will continue to accelerate the development of its ADC products, with the aim of bringing more and better solutions to patients globally."

The Company is poised to initiate international multicenter phase II clinical studies across the United States, China, the European Union, and other regions, aiming to further clarify the optimal dosage, effectiveness, and safety of RC88 monotherapy.

About RemeGen Co. Ltd.

Founded in 2008, RemeGen (9995.HK, SHA: 688331) is a leading biopharmaceutical company in China committed to providing solutions to the unmet clinical needs of patients suffering from life-threatening illnesses. RemeGen has research laboratories and offices throughout China and the United States. The company is committed to discovering, developing, and commercializing innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology, and ophthalmic diseases. For more details, please visit: www.remegen.com

About RC88

RC88 is a novel antibody drug conjugate (ADC) independently developed by RemeGen targeting mesothelin (MSLN). It uses the company's independently developed innovative bridging technology to connect antibodies and drugs. The structure includes MSLN-targeting antibodies, cleavable connections and a small fraction of cytotoxins (MMAE) can mediate the endocytosis of antibodies by binding to MSLN-positive tumor MSLN-positive tumor cells, thereby effectively delivering cytotoxins to cancer cells and achieving improved tumor killing effects.

SOURCE RemeGen Co., Ltd

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构